Dyadic International (DYAI) Q3 Investor Summit Group Virtual Conference 2026 earnings summary

Strategic transformation and commercialization

• Transitioned from R&D to commercial stage, diversifying revenue through product sales, licensing, and profit-sharing.

• Focused on scalable commercialization with a lean structure and disciplined capital deployment.

• Commercialized multiple products across life sciences, food nutrition, and bioindustrial segments.

• Signed global distribution agreements and established recurring revenue streams.

• Demonstrated ability to launch products with partners in under two years.

Technology and platform differentiation

• Utilizes a filamentous fungal-based gene expression system for non-animal protein and enzyme production.

• C1 platform optimized for high-value, complex proteins in life sciences; Dapibus platform for cost-efficient production in food and bioindustrial markets.

• Proven safety of C1 platform in human administration through a phase I study.

• Industrialized platform enables high productivity and scalability, differentiating from traditional lab-based systems.

Market focus and partnerships

• Core segments: life sciences (cell culture media, diagnostics, gene therapy), food nutrition (non-animal dairy proteins), and bioindustrial (biofuels, biomass enzymes).

• Key partnerships include Proliant Health & Biologicals (life sciences), Inzymes ApS (food), and Fermbox Bio (bioindustrial).

• Products like AlbuFree DX, chymosin, and EN3ZYME have launched through partners, generating initial revenues.

• Partner-driven, capital-light model in food and nutrition to enable rapid scale-up.